<DOC>
	<DOCNO>NCT01076283</DOCNO>
	<brief_summary>This pilot trial goal demonstrate feasibility study test effect baclofen laboratory experiment use cue-reactivity alcohol-self administration paradigm non-treatment seek alcohol-dependent subject .</brief_summary>
	<brief_title>A Study Biobehavioral Mechanisms Baclofen Alcohol Drinking</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Cyproheptadine</mesh_term>
	<criteria>must male female 21 65 year old ( inclusive ) . participant must meet criterion current Diagnostic Statistical Manual Mental Disorders , fourth edition , text revision ( DSMIVTR ) diagnosis alcohol dependence , support Structured Clinical Interview DSMIVTR Axis I Disorders Patient Edition ( SCIDI/P ) . participant must meet criterion heavy drinking , define average ≥4 drinks/day woman ≥5 drinks/day men consecutive 30day period within 90 day prior baseline evaluation ( see : Anton et al , 2006 ) . The genderspecific baseline choose represent heavy drinking exceeds empirically base level moderate alcohol use result alcoholrelated problem woman consume ≥4 drinks/day , men consume ≥5 drinks/day ( SanchezCraig et al , 1995 ) . participant must good health confirm medical history , physical examination , ECG , lab test . female must postmenopausal least one year , surgically sterile , practice effective method birth control entry throughout study ; negative urine pregnancy test visit . participant must willing take oral medication adhere study procedure . Exclusion criterion : individual express interest treatment alcoholism . pregnancy breast feed woman use adequate form birth control positive urine drug screen baseline illegal substance ( urine drug screen may repeat screen period ) . individual diagnose current substance dependence diagnosis , alcohol nicotine . meet DSMIV Axis I criteria lifetime diagnosis schizophrenia , bipolar disorder , psychosis . active illness within past 6 month Visit 1 meet DSMIV criterion diagnosis Major Depressive Disorder ( MDD ) Anxiety Disorder . Subjects history suicide exclude . clinically significant medical abnormality ( i.e. , unstable hypertension , ECG , bilirubin &gt; 150 % upper normal limit , ALT AST elevation &gt; 300 % upper normal limit , creatinine clearance ≤ 60 dl/min ) . current use psychotropic medication discontinue may effect alcohol consumption may interact baclofen cyproheptadine . medical contraindication use baclofen cyproheptadine . history adverse reaction hypersensitivity baclofen cyproheptadine . individual reasonable expectation institutionalize course trial . participant significant alcohol withdrawal symptom , define Clinical Institute Withdrawal Assessment Alcohol ( CIWAAr ) &gt; 10 . history seizure ( e.g . epilepsy ) . subject participate behavioral and/or pharmacological study within past 90 day .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>baclofen</keyword>
	<keyword>alcoholism</keyword>
	<keyword>urge</keyword>
	<keyword>crave</keyword>
	<keyword>alcohol drinking</keyword>
	<keyword>biobehavioral mechanism baclofen alcoholism</keyword>
</DOC>